EGFR and esophageal squamous cell carcinoma: However, the overall survival was not significantly different in the two treatment arms in the whole ESCC population (11.5 months in the chemotherapy + cetuximab group compared with 10.5 months in the chemotherapy alone group); however, a clear trend of overall survival was observed considering only the EGFR-amplified patients (17.1 months versus 6 months in the cetuximab + chemotherapy and chemotherapy alone, respectively) [66].